| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Tony Yaksh | |
| Martin Schmelz | |||
| Lars Viktrup | |||
| John Farrar | |||
| Anne-Marie Malfait | |||
| Leslie Tive | |||
| Patrick Mantyh | |||
| P2860 | cites work | Peripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neurones. | Q50757656 |
| A phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. | Q50961307 | ||
| Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. | Q51707357 | ||
| Nerve growth factor receptor TrkA is down-regulated during postnatal development by a subset of dorsal root ganglion neurons. | Q52194442 | ||
| Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. | Q53579192 | ||
| How central is central post-stroke pain? The role of afferent input in post-stroke neuropathic pain: a prospective open-label pilot study. | Q53835533 | ||
| Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. | Q54485357 | ||
| Neuropathic-like symptoms and the association with joint-specific function and quality of life in patients with hip and knee osteoarthritis. | Q55313849 | ||
| Nerve growth factor-induced hyperalgesia in the neonatal and adult rat | Q56980397 | ||
| Mechanisms that drive bone pain across the lifespan | Q57790366 | ||
| Angiogenesis in the synovium and at the osteochondral junction in osteoarthritis | Q59151146 | ||
| Sodium channel expression in NGF-overexpressing transgenic mice | Q60681175 | ||
| Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis | Q60701636 | ||
| Nerve growth factor expression and innervation of the painful intervertebral disc | Q61699202 | ||
| Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans | Q73089963 | ||
| Nerve growth factor modifies the expression of inflammatory cytokines by mast cells via a prostanoid-dependent mechanism | Q77320480 | ||
| Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur | Q80635082 | ||
| Nerve growth factor content in dorsal root ganglion as related to changes in pain behavior in a rat model of experimental lumbar disc herniation | Q81256914 | ||
| Efficacy and safety of tanezumab in the treatment of chronic low back pain | Q84421146 | ||
| Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen | Q85664357 | ||
| The current status of imaging in anti-NGF clinical trials | Q86359689 | ||
| Editorial: Pain Relief in Osteoarthritis: The Potential for a Perfect Storm | Q86663091 | ||
| Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments | Q88696163 | ||
| Recent advances in understanding neurotrophin signaling | Q26740307 | ||
| Mechanisms of low back pain: a guide for diagnosis and therapy | Q26740642 | ||
| Anti-nerve growth factor in pain management: current evidence | Q26746194 | ||
| Osteoarthritis joint pain: the cytokine connection | Q26859004 | ||
| Neuropathic low back pain in clinical practice | Q28073412 | ||
| Arthritis and pain. Neurogenic origin of joint pain | Q28210860 | ||
| Disruption of the neurotrophin-3 receptor gene trkC eliminates la muscle afferents and results in abnormal movements | Q28251523 | ||
| The anti-NGF antibody muMab 911 both prevents and reverses pain behaviour and subchondral osteoclast numbers in a rat model of osteoarthritis pain | Q28388389 | ||
| Role of low-affinity nerve growth factor receptor inhibitory antibody in reducing pain behavior and calcitonin gene-related Peptide expression in a rat model of wrist joint inflammatory pain | Q28571139 | ||
| Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord | Q28571753 | ||
| Complex regional pain syndrome: a recent update. | Q30238767 | ||
| Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment | Q30458126 | ||
| Exuberant sprouting of sensory and sympathetic nerve fibers in nonhealed bone fractures and the generation and maintenance of chronic skeletal pain | Q30604523 | ||
| The discordance between clinical and radiographic knee osteoarthritis: a systematic search and summary of the literature | Q33365812 | ||
| Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. | Q33728157 | ||
| Functional distinction between NGF-mediated plasticity and regeneration of nociceptive axons within the spinal cord | Q33918449 | ||
| Pain-related sensory innervation in monoiodoacetate-induced osteoarthritis in rat knees that gradually develops neuronal injury in addition to inflammatory pain | Q33934561 | ||
| Angiogenesis and nerve growth factor at the osteochondral junction in rheumatoid arthritis and osteoarthritis. | Q34117139 | ||
| Proinflammatory mediators, stimulators of sensory neuron excitability via the expression of acid-sensing ion channels. | Q34165309 | ||
| Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis | Q34203748 | ||
| Osteoarthritis: a disease of the joint as an organ | Q34258870 | ||
| A mutation in the nerve growth factor beta gene (NGFB) causes loss of pain perception | Q34300023 | ||
| Mechanisms of inflammatory pain | Q34312281 | ||
| Signaling pathways that mediate nerve growth factor-induced increase in expression and release of calcitonin gene-related peptide from sensory neurons | Q34329997 | ||
| Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain | Q34356398 | ||
| Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? | Q34800447 | ||
| Structural associations of symptomatic knee osteoarthritis | Q35023177 | ||
| Antagonism of nerve growth factor-TrkA signaling and the relief of pain | Q35064559 | ||
| Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain | Q35421746 | ||
| Painful, degenerating intervertebral discs up-regulate neurite sprouting and CGRP through nociceptive factors | Q35867969 | ||
| Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis. | Q36050186 | ||
| Existence of a neuropathic pain component in patients with osteoarthritis of the knee | Q36053417 | ||
| Neuroplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint | Q36067194 | ||
| Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials | Q36236043 | ||
| Sensory and sympathetic nerve fibers undergo sprouting and neuroma formation in the painful arthritic joint of geriatric mice | Q36245918 | ||
| Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis. | Q36871346 | ||
| Role of the brain-derived neurotrophic factor at glutamatergic synapses. | Q37024497 | ||
| Inhibition of endogenous NGF degradation induces mechanical allodynia and thermal hyperalgesia in rats | Q37079325 | ||
| Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort | Q37118237 | ||
| The epidemiology and impact of pain in osteoarthritis | Q37121928 | ||
| Nociceptor sensitization in pain pathogenesis | Q37254618 | ||
| TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain | Q37289615 | ||
| PKCδ null mutations in a mouse model of osteoarthritis alter osteoarthritic pain independently of joint pathology by augmenting NGF/TrkA-induced axonal outgrowth | Q37471618 | ||
| Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model | Q37604491 | ||
| Intervertebral disc, sensory nerves and neurotrophins: who is who in discogenic pain? | Q37747851 | ||
| Signaling in innate immunity and inflammation | Q37980557 | ||
| The prevalence of chronic pain with an analysis of countries with a Human Development Index less than 0.9: a systematic review without meta-analysis | Q38018634 | ||
| Quantitative sensory testing in painful osteoarthritis: a systematic review and meta-analysis | Q38026383 | ||
| The role of AMPA receptors in postsynaptic mechanisms of synaptic plasticity | Q38288076 | ||
| A systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or knee | Q38295106 | ||
| Efficacy, Safety, and Tolerability of Fulranumab as an Adjunctive Therapy in Patients With Inadequately Controlled, Moderate-to-Severe Chronic Low Back Pain: A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Dose-loading Phase II Study | Q38393353 | ||
| Induction of nerve growth factor expression and release by mechanical and inflammatory stimuli in chondrocytes: possible involvement in osteoarthritis pain | Q38646694 | ||
| Nerve Growth Factor Antagonists: Is the Future of Monoclonal Antibodies Becoming Clearer? | Q38665353 | ||
| Development of an imaging mitigation strategy for patient enrolment in the tanezumab nerve growth factor inhibitor (NGF-ab) program with a focus on eligibility assessment. | Q38721211 | ||
| Pain sensation in human osteoarthritic knee joints is strongly enhanced by diabetes mellitus. | Q38722532 | ||
| Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment | Q38774334 | ||
| Central sensitization in chronic low back pain: A narrative review. | Q38803435 | ||
| Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models? | Q38817280 | ||
| Rethinking chronic pain in a primary care setting | Q38831661 | ||
| Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies | Q39070631 | ||
| Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial | Q39171996 | ||
| Blocking the tropomyosin receptor kinase A (TrkA) receptor inhibits pain behaviour in two rat models of osteoarthritis | Q39184757 | ||
| Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain | Q39210251 | ||
| Nerve Growth Factor and Pain Mechanisms | Q39261395 | ||
| When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program | Q40337398 | ||
| NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. | Q40345535 | ||
| Nerve growth factor regulates substance P in adult sensory neurons through both TrkA and p75 receptors | Q40349019 | ||
| Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia | Q40555097 | ||
| Upregulation of bradykinin B2 receptor expression by neurotrophic factors and nerve injury in mouse sensory neurons | Q40748877 | ||
| Analgesia via blockade of NGF/TrkA signaling does not influence fracture healing in mice | Q41069496 | ||
| Regulation of voltage-gated ion channels by NGF and ciliary neurotrophic factor in SK-N-SH neuroblastoma cells | Q41404665 | ||
| Mediator release from mast cells by nerve growth factor. Neurotrophin specificity and receptor mediation. | Q41542012 | ||
| Altered expression of nerve growth factor in the skin of transgenic mice leads to changes in response to mechanical stimuli. | Q42475415 | ||
| Differential effects of NGF and BDNF on voltage-gated calcium currents in embryonic basal forebrain neurons | Q42485034 | ||
| p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia | Q42526677 | ||
| Immunocytochemical localization of trkA receptors in chemically identified subgroups of adult rat sensory neurons. | Q42578333 | ||
| Extensive sprouting of sensory afferents and hyperalgesia induced by conditional expression of nerve growth factor in the adult spinal cord. | Q42800909 | ||
| NGF-TrkA signaling in sensory nerves is required for skeletal adaptation to mechanical loads in mice | Q43083614 | ||
| Sympathetic sprouting in the dorsal root ganglion after spinal nerve ligation: evidence of regenerative collateral sprouting | Q43548487 | ||
| Axonal hyperexcitability after combined NGF sensitization and UV-B inflammation in humans | Q44121801 | ||
| Nerve growth factor induces sensitization of nociceptors without evidence for increased intraepidermal nerve fiber density | Q44664758 | ||
| Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain | Q45788038 | ||
| Mechanisms of Osteoarthritic Pain. Studies in Humans and Experimental Models | Q45792955 | ||
| Efficacy of nerve growth factor antibody in a knee osteoarthritis pain model in mice. | Q45907144 | ||
| Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization | Q46442854 | ||
| An overview of pathways encoding nociception | Q46868460 | ||
| Immunohistochemical localization of nerve growth factor, tropomyosin receptor kinase A, and p75 in the bone and articular cartilage of the mouse femur. | Q47111283 | ||
| Nerve growth factor locally sensitizes nociceptors in human skin. | Q47592564 | ||
| Behavioral and histological effects of endoneurial administration of nerve growth factor: possible implications in neuropathic pain | Q47611891 | ||
| Development of an In Vivo Mouse Model of Discogenic Low Back Pain. | Q47705035 | ||
| Human vs. Mouse Nociceptors - Similarities and Differences | Q47788067 | ||
| Nerve growth factor-induced synapse-like structures in contralateral sensory ganglia contribute to chronic mirror-image pain | Q48103917 | ||
| Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord | Q48617112 | ||
| Nerve growth factor and brain-derived neurotrophic factor mRNAs are regulated in distinct cell populations of rat heart after ischaemia and reperfusion | Q48849158 | ||
| Cost of pain medication to treat adult patients with nonmalignant chronic pain in the United States. | Q50461598 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 10 | |
| P921 | main subject | chronic pain | Q1088113 |
| P304 | page(s) | 2210-2220 | |
| P577 | publication date | 2019-10-01 | |
| P1433 | published in | Pain | Q2317902 |
| P1476 | title | Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety | |
| P478 | volume | 160 |
| Q101574342 | EZH2 inhibition reduces cartilage loss and functional impairment related to osteoarthritis |
| Q92518513 | Fresh human amniotic membrane effectively promotes the repair of injured common peroneal nerve |
| Q97644214 | The Efficacy of Nerve Growth Factor Antibody for the Treatment of Osteoarthritis Pain and Chronic Low-Back Pain: A Meta-Analysis |
| Q90702055 | Understanding the genetic basis of congenital insensitivity to pain |
Search more.